Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
This is a prospective study including patients presenting in aggregate primary lesions
affected by nodular BCC of the eyelid (all subjects were submitted to incisional biopsy at 2
mm punch) at the commencement of this study. All were submitted to a local treatment with
Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average). All
subjects were submitted to a new incisional biopsy at 2 mm punch, after 12 weeks of
treatment, and all of them were monitored monthly up to now.If positive biopsy (residue
tumor) cases will managed with surgery.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
post-treatment biopsy
post-treatment biopsy
Yes
E M macedo
Principal Investigator
University of Sao Paulo
Brazil: Ethics Committee
0559/07
NCT00803907
December 2008
February 2013
Name | Location |
---|